Bionomics Ltd - Product Pipeline Review - 2016

  • ID: 4043289
  • Company Profile
  • 47 pages
  • Global Markets Direct
1 of 4
Bionomics Ltd - Product Pipeline Review - 2016

Summary:

‘Bionomics Ltd - Product Pipeline Review - 2016’, provides an overview of the Bionomics Ltd’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Bionomics Ltd, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from our proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information.

Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope:

- The report provides a snapshot of the pipeline therapeutic landscape of Bionomics Ltd
- The report provides overview of Bionomics Ltd including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report assesses Bionomics Ltd’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report features Bionomics Ltd’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to Buy:

- Evaluate Bionomics Ltd’s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Bionomics Ltd
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Bionomics Ltd’s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 4
Introduction

Bionomics Ltd Snapshot

Bionomics Ltd Overview

Key Facts

Bionomics Ltd - Research and Development Overview

Key Therapeutic Areas

Bionomics Ltd - Pipeline Review

Pipeline Products by Stage of Development

Pipeline Products - Monotherapy

Pipeline Products - Out-Licensed Products

Out-Licensed Products/Combination Treatment Modalities

Bionomics Ltd - Pipeline Products Glance

Bionomics Ltd - Clinical Stage Pipeline Products

Phase II Products/Combination Treatment Modalities

Phase I Products/Combination Treatment Modalities

Bionomics Ltd - Early Stage Pipeline Products

IND/CTA Filed Products/Combination Treatment Modalities

Preclinical Products/Combination Treatment Modalities

Bionomics Ltd - Drug Profiles

BL-011256 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BNC-101 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BNC-105 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BNC-164 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BNC-210 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BNC-420 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Drug for Dyskinesia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Drug for Pain - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Drugs for Solid Tumors - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Drugs to Inhibit MELK for Solid Tumors - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Agonize GABA-A Receptor For Epilepsy - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Block Nav 1.7 Channels for Chronic And Neuropathic Pain - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Bionomics Ltd - Pipeline Analysis

Bionomics Ltd - Pipeline Products by Target

Bionomics Ltd - Pipeline Products by Route of Administration

Bionomics Ltd - Pipeline Products by Molecule Type

Bionomics Ltd - Pipeline Products by Mechanism of Action

Bionomics Ltd - Dormant Projects

Bionomics Ltd - Discontinued Pipeline Products

Discontinued Pipeline Product Profiles

Drug to Inhibit RET Kinase for Lung and Thyroid Cancer

Bionomics Ltd - Locations And Subsidiaries

Head Office

Other Locations & Subsidiaries

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables:

Bionomics Ltd, Key Facts

Bionomics Ltd - Pipeline by Indication, 2016

Bionomics Ltd - Pipeline by Stage of Development, 2016

Bionomics Ltd - Monotherapy Products in Pipeline, 2016

Bionomics Ltd - Out-Licensed Products in Pipeline, 2016

Bionomics Ltd - Out-Licensed Products/ Combination Treatment Modalities, 2016

Bionomics Ltd - Phase II, 2016

Bionomics Ltd - Phase I, 2016

Bionomics Ltd - IND/CTA Filed, 2016

Bionomics Ltd - Preclinical, 2016

Bionomics Ltd - Pipeline by Target, 2016

Bionomics Ltd - Pipeline by Route of Administration, 2016

Bionomics Ltd - Pipeline by Molecule Type, 2016

Bionomics Ltd - Pipeline Products by Mechanism of Action, 2016

Bionomics Ltd - Dormant Developmental Projects,2016

Bionomics Ltd - Discontinued Pipeline Products, 2016

Bionomics Ltd, Subsidiaries

List of Figures:

Bionomics Ltd - Pipeline by Top 10 Indication, 2016

Bionomics Ltd - Pipeline by Stage of Development, 2016

Bionomics Ltd - Monotherapy Products in Pipeline, 2016

Bionomics Ltd - Pipeline by Target, 2016

Bionomics Ltd - Pipeline by Route of Administration, 2016

Bionomics Ltd - Pipeline by Molecule Type, 2016

Bionomics Ltd - Pipeline Products by Mechanism of Action,
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
Note: Product cover images may vary from those shown
Adroll
adroll